Systemic amyloidosis: Are we moving ahead?

Netherlands Journal of Medicine

Volumn 62, Issue 4, 2004, Pages 104-105

  Merlini, G ^a,b  

^a Biotechnology Research Laboratory   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PARAPROTEIN; VINCRISTINE;

AMYLOIDOSIS; AUTONOMIC NEUROPATHY; CARDIOTOXICITY; DIAGNOSTIC ACCURACY; DISEASE COURSE; EDITORIAL; ELECTRON MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PROGNOSIS; REMISSION;

AMYLOIDOSIS; HUMANS; PROGNOSIS;

EID: 4143091477     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
2. Hazenberg BPC, Gameren II van, Bijzet J, Jager PL, Rijswijk MH van. Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med 2004;62(4):121-8.
3. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
4. Arbustini E, Morbini P, Verga L, et al. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloidosis 1997;4:157-70.
5. Palladini G, Obici L, Merlini G. Hereditary amyloidosis. N Engl J Med 2002;347:1206.
6. Olsen KE, Sletten K, Westermark P. Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: Kappa IV immunoglobulin light chain. Biochem Biophys Res Commun 1998;245:713-6.
7. Kaplan B, Hrncic R, Murphy CL, Gallo G, Weiss DT, Solomon A. Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts in tissue. Meth Enzymol 1999;309:67-81.
8. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.
9. Gameren II van, Lokhorst H, Hazenberg BPC, Vellenga E. Therapeutic options in systemic AL amyloidosis. Neth J Med 2004;62(4):106-13.
10. Palladini G, Anesi E, Perfetti V, et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001;113:1044-6.
11. Palladini G, Perfetti V, Obici L, et al. The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation. Blood 2003;Dec 18 [Epub ahead of print].
12. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92:2959-63.
13. De Lorenzi E, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V. Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". Curr Med Chem 2004;in press.